SYK
Stryker CorporationNYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 22, 12:12 PM
    • Investors' sour mood with Medtronic (MDT -10.2%) over its modest 2% fiscal Q2 revenue miss has spread to Abbott (ABT -4.6%), Edwards Lifesciences (EW -5.6%) and Boston Scientific (BSX -4.4%).
    • Others feeling the pinch are Stryker (SYK -2.3%) and C.R. Bard (BCR -3.6%).
    | Tue, Nov. 22, 12:12 PM | 17 Comments
  • Tue, Nov. 22, 9:55 AM
    • Amedica (AMDA -30%appoints Dana Lyons as VP of Sales and Marketing. He joins the firm from Stryker (SYK -1.5%)  where he served in various senior sales leadership roles.
    • On the positive side, the FDA has notified the company that its pedicle screw system, Taurus, has been cleared for commercialization.
    • On the negative front, the FDA rejected its 510(k) application seeking approval of its spinal fusion device Valeo C+CsC, despite its successful use in Europe. The company says it is working with the agency to clarify a regulatory path forward.
    | Tue, Nov. 22, 9:55 AM | 7 Comments
  • Fri, Nov. 4, 8:16 AM
    • Almost Family (NASDAQ:AFAM) upgraded to Outperform from Neutral by Baird. Price target raised to $55 (35% upside) from $44.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Outperform from Market Perform by BMO Capital. Price target lowered to $84 (17% upside) from $98.
    • Dentsply Sirona (NASDAQ:XRAY) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $69 (16% upside) from $65.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Strong Buy from Buy by Needham. Price target lowered to $148 (44% upside) from $150.
    • Stryker (NYSE:SYK) upgraded to Market Perform from Underperform with a $125 (8% upside) price target by BMO Capital.
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Neutral by Credit Suisse. Price target lowered to $52 (33% upside) from $59.
    • Cempra (NASDAQ:CEMP) downgraded to Hold from Buy by Stifel Nicolaus. Price target lowered to $8 (6% upside) from $37. Downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $6 (21% downside risk) from $25. Downgraded to Underperform from Outperform by Baird. Price target lowered to $6 (21% downside risk) from $33.
    • Diplomat Pharmacy (NYSE:DPLO) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $18 (39% upside) from $35. Downgraded to Market Perform by Citigroup and Avondale Partners.
    • WebMD (NASDAQ:WBMD) downgraded to Neutral from Buy by Mizuho Securities. Price target lowered to $52 (5% upside) from $63.
    • Pfizer (NYSE:PFE) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $33 (10% upside) from $40. Downgraded to Hold from Buy by Argus.
    • Adeptus Health (NYSE:ADPT) downgraded to Underperform from Buy by Bank of America. Downgraded to Hold from Buy by Jefferies. Price target lowered to $13 (48% upside) from $77.
    • Sangamo BioSciences (NASDAQ:SGMO) downgraded to Neutral from Overweight by Wedbush and Piper Jaffray. Price targets lowered to $4 (25% upside) from $30 and $5 (56% upside) from $9, respectively.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Buy by Citigroup and to Hold from Buy by DNB Markets.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $60 (7% upside) from $70.
    | Fri, Nov. 4, 8:16 AM | 18 Comments
  • Thu, Oct. 27, 5:12 PM
    • Stryker (NYSE:SYK) Q3 results ($M): Net Sales: 2,833 (+17.1%); Orthopedics: 1,077 (+5.6%); MedSurg: 1,253 (+33.0%); Neurotechnology and Spine: 503 (+9.7%).
    • Net Income: 355 (+17.9%); Non-GAAP Net Income: 526 (+10.5%); EPS: 0.94 (+19.0%); Non-GAAP EPS: 1.39 (+11.2%); CF Ops (9 mo.): 1,164 (+410.5%).
    • 2016 Guidance: Sales Growth: 6.0 - 6.5%; EPS: $4.42 - 4.63: Non-GAAP EPS: $5.75 - 5.80 from $5.70 - 5.80.
    • Q4 Guidance: EPS: $1.41 - 1.62; Non-GAAP EPS: $1.73 - 1.78.
    • Consensus view was EPS of $1.37 on revenues of $2.8B.
    • Shares are up 1% after hours on light volume.
    | Thu, Oct. 27, 5:12 PM
  • Thu, Oct. 27, 4:50 PM
    • Stryker (NYSE:SYK): Q3 EPS of $1.39 beats by $0.02.
    • Revenue of $2.83B (+16.9% Y/Y) beats by $20M.
    • Shares +0.03%.
    • Press Release
    | Thu, Oct. 27, 4:50 PM | 1 Comment
  • Wed, Oct. 26, 5:35 PM
  • Fri, Oct. 21, 7:40 AM
    • SCYNEXIS (NASDAQ:SCYX) initiated with Buy rating and $14 (272% upside) price target by H.C. Wainwright.
    • Catalent (NYSE:CTLT) initiated with Overweight rating and $29 (19% upside) price target by KeyBanc.
    • Coherus Biosciences (NASDAQ:CHRS) initiated with Outperform rating and $40 (32% upside) price target by Baird.
    • Amarin (NASDAQ:AMRN) initiated with Buy rating and $5 (58% upside) price target by Citigroup.
    • AC Immune (Pending:ACIU) initiated with Outperform rating and $18 (20% upside) price target by Credit Suisse.
    • Sarepta Therapeutics (NASDAQ:SRPT) initiated with Outperform rating and $68 (39% upside) price target by Credit Suisse.
    • Neurocrine Biosciences (NASDAQ:NBIX) initiated with Buy rating and $62 (36% upside) price target by Needham.
    • AbbVie (NYSE:ABBV) initiated with Market Perform rating and $70 (13% upside) price target by Leerink Swann.
    • Stryker (NYSE:SYK) initiated with Buy rating and $140 (22% upside) price target by SunTrust Robinson Humphrey.
    | Fri, Oct. 21, 7:40 AM | 3 Comments
  • Wed, Sep. 28, 8:10 AM
    | Wed, Sep. 28, 8:10 AM
  • Wed, Sep. 14, 8:37 AM
    • Stryker (NYSE:SYK) inks an agreement to acquire privately held Instratek (Restore Surgical LLC) for an undisclosed sum. The transaction should close by year end.
    • Houston, TX-based Instratek develops orthopedic implants and endoscopic instrumentation for use in extremity surgery (hand and foot conditions).
    | Wed, Sep. 14, 8:37 AM | 1 Comment
  • Thu, Jul. 21, 4:46 PM
    • Stryker (NYSE:SYK) Q2 results ($M): Net Sales: 2,840 (+16.8%); Operating Expenses: 1,342 (+14.1%); Orthopedics: 1,082 (+4.6%); MedSurg: 1,258 (+33.8%); Neurotechnology and Spine: 500 (+9.3%).
    • Net Income: 380 (-3.1%); EPS: 1.00 (-2.9%).
    • 2016 Guidance: Organic sales growth: 6.0 - 6.5% from 5.5 - 6.5%; Non-GAAP EPS: $5.70 - 5.80 from $5.65 - 5.80.
    • Q3 Guidance: Non-GAAP EPS: $1.33 - 1.38.
    | Thu, Jul. 21, 4:46 PM | 1 Comment
  • Thu, Jul. 21, 4:37 PM
    • Stryker (NYSE:SYK): Q2 EPS of $1.39 beats by $0.02.
    • Revenue of $2.84B (+16.9% Y/Y) beats by $50M.
    • Shares -3.9%.
    • Press Release
    | Thu, Jul. 21, 4:37 PM
  • Wed, Jul. 20, 5:35 PM
    | Wed, Jul. 20, 5:35 PM | 13 Comments
  • Mon, Jun. 27, 11:16 AM
    | Mon, Jun. 27, 11:16 AM | 83 Comments
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Thu, Apr. 21, 10:23 AM
    • Stryker (SYK -0.3%) Q1 results: Revenues: $2,495M (+4.9%); R&D Expense: $159M (+4.6%); SG&A: $944M (+5.8%); Operating Income: $519M (+27.8%); Net Income: $402M (+79.5%); EPS: $1.07 (+84.5%); Non-GAAP EPS: $1.24 (+11.7%); Quick Assets: $6,976M (+106.5%).
    • Q2 Guidance: Non-GAAP EPS: $1.33 - 1.38.
    • 2016 Guidance: Organic sales growth: 5.5 - 6.5% from 5 - 6%; Non-GAAP EPS: $5.65 - 5.80 from $5.57 - 5.77.
    | Thu, Apr. 21, 10:23 AM | 4 Comments
  • Wed, Apr. 20, 4:49 PM
    • Stryker (NYSE:SYK): Q1 EPS of $1.24 beats by $0.04.
    • Revenue of $2.5B (+5.0% Y/Y) beats by $30M.
    | Wed, Apr. 20, 4:49 PM | 1 Comment